Medicare policy boosts iMDx transplant testing frequency
Insight Molecular Diagnostics Inc. secured a favorable Medicare policy on July 16, 2026, expanding coverage for dd-cfDNA testing. The policy increases surveillance testing frequency for kidney and heart transplants, removing the testing ceiling for years four and beyond. This supports iMDx's $2 billion market opportunity and its strategy to sell GraftAssureDx kits for in-house testing.
*this image is generated using AI for illustrative purposes only.
Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy on July 16, 2026, that expands coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care. The policy, issued by the MolDX program under the Centers for Medicare & Medicaid Services (CMS), increases the allowed frequency of surveillance testing. This development supports the commercial adoption of the company's GraftAssure family of assays and aligns with its strategy to enable in-house testing at transplant centers.
The final policy establishes a baseline for long-term surveillance testing, providing reimbursement clarity for hospitals, physicians, and laboratories. It cites iMDx-affiliated research, affirming the company's scientific leadership. The policy allows for higher testing frequencies compared to the previous draft, which iMDx believes strengthens the economic case for transplant centers to bring dd-cfDNA testing in-house.
Testing Frequency Increases
The final policy increases covered surveillance testing frequencies across all organ types relative to the draft policy. iMDx's immediate focus is on kidney transplant testing, followed by heart transplant testing. The changes are outlined below:
| Time Period | Kidney Transplant Tests | Heart Transplant Tests |
|---|---|---|
| Year 1 | 6 tests | 12 tests |
| Years 2 and 3 | 4 tests per year | 4 tests per year |
| Years 4 and beyond | No ceiling (if clinically useful) | No ceiling (if clinically useful) |
In the first year post-transplant, reimbursable kidney surveillance testing increased from four tests in the draft policy to six tests in the final policy. Heart testing frequency remains unchanged at twelve tests. For the second and third years, the frequency for both kidney and heart transplant patients doubled from two tests per year to four tests per year. For the remaining life of the patient, the final policy removes the testing rate ceiling proposed in the draft, provided the testing frequency has clinical utility.
Reimbursement and Commercial Strategy
iMDx's flagship technology, GraftAssureCore, has a Medicare reimbursement rate of $2,753 per result. This rate applies to the lab-developed test performed at the company's Tennessee laboratory. The company expects this rate to extend to GraftAssureDx through a "bridging" process after FDA marketing authorization is achieved. iMDx aims to sell GraftAssureDx kits to transplant centers for in-house testing.
The company's product portfolio includes GraftAssureCore, a laboratory-developed test; GraftAssureIQ, a research-use-only kit; and GraftAssureDx, an in vitro diagnostic kit under FDA review. The higher testing frequency outlined in the policy is favorable to the company's publicly stated $2 billion total addressable market for kitted transplanted organ testing.
How will the removal of the testing rate ceiling for years four and beyond impact long-term revenue projections for iMDx?
What is the expected timeline for FDA marketing authorization of GraftAssureDx to initiate the reimbursement bridging process?
How might private insurers adjust their coverage policies in response to CMS's expanded frequency guidelines?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
